Clinical Implications of Serum 25-Hydroxyvitamin D Status after 5-Year Adjuvant Endocrine Therapy for Late Recurrence of Hormone Receptor-positive Breast Cancer.

Seung Taek Lim Ye Won Jeon Hongki Gwak Young Jin Suh

Published in: Journal of breast cancer (2020)

We found that 25(OH)D deficiency after the 5-year adjuvant endocrine therapy was associated with worse LRFS among HR-positive breast cancer patients, particularly with respect to regional LN, bone, and visceral recurrence.

Keyphrases

positive breast cancer
early stage
free survival
bone mineral density
insulin resistance
soft tissue
replacement therapy
metabolic syndrome
type diabetes
stem cells
bone regeneration